Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus
Trial ID or NCT#
NCT00379145
Status
NOT RECRUITING
Purpose
RATIONALE: Drugs used in chemotherapy, such as trabectedin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well trabectedin works in treating patients with advanced, persistent, or recurrent leiomyosarcoma of the uterus.
Official Title
A Phase II Evaluation of Trabectedin (Yondelis, R279741) in the Treatment of Advanced, Persistent, or Recurrent Uterine Leiomyosarcomas
Eligibility Criteria
Ages Eligible for Study: 18 Years to 120 Years
Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers: No
Investigator(s)
Nelson Teng
Contact us to find out if this trial is right for you.
Contact
Maureen Sutton
6507259167
View on ClinicalTrials.gov
